Partner Therapeutics, Inc. (PTx)
19 Muzzey Street
About Partner Therapeutics, Inc. (PTx)
We're all in for the fight against cancer. Partner Therapeutics (PTx) is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients. We are united in our passion for improving the treatment of cancer and our desire to make a meaningful contribution to outcomes.
The patient is number one. We believe that being a cancer company begins and ends with the patient. We strive to support patient needs throughout their treatment journey to help them make the treatment choices that are right for them and their loved ones.
9 articles with Partner Therapeutics, Inc. (PTx)
Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine® (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhuGM-CSF), for the potential treatment of Stage IIb-IV melanoma.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Partner Therapeutics Receives FDA Orphan Drug Designation for Leukine® for the Treatment of Pulmonary Alveolar Proteinosis
Partner Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine®.
Partner Therapeutics (PTx) Announces US FDA Approval of Leukine® (sargramostim) for the Treatment of Acute Radiation Syndrome
Improves survival when initiated 48 hours after radiation exposure
Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Partner Therapeutics, Inc. (PTx), an integrated biopharmaceutical company.
Partner Therapeutics (PTx) Announces the Appointment of Ellen Hukkelhoven Ph.D. and Terry Gould to its Board of Directors
These will add their extensive experience and networks to PTx team.
Partner Therapeutics (PTx) Announces the Appointment of Colleen Mockbee as Chief Development Officer
Former Lilly Executive will oversee Development, Regulatory Affairs and Quality
Only a week after launch, Partner Therapeutics acquired the global rights to Leukine from Sanofi.
Biotech and pharma execs Robert Mulroy and Dr. Debasish Roychowdhury announced today the launch of Partner Therapeutics, or PTx.